menu
    • menu
    [{"orgOrder":0,"company":"University of Tokyo ","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Nafamostat","moa":"Serine protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Tokyo ","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Tokyo \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"University of Tokyo \/ Not Applicable"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Nafamostat","moa":"Serine protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Ensysce Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ensysce Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Nafamostat","moa":"Serine protease","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Not Applicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"The University of Tokyo","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Nafamostat","moa":"Serine protease","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ The University of Tokyo","highestDevelopmentStatusID":"1","companyTruncated":"Daiichi Sankyo \/ The University of Tokyo"},{"orgOrder":0,"company":"Mucokinetica","sponsor":"Covistat","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Nafamostat","moa":"Serine protease","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mucokinetica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Mucokinetica \/ Covistat","highestDevelopmentStatusID":"1","companyTruncated":"Mucokinetica \/ Covistat"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Nafamostat","moa":"Serine protease","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Chong Kun Dang Pharm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Chong Kun Dang Pharm \/ Not Applicable"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Nafamostat","moa":"TMPRSS2","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ensysce Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ensysce Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Nafamostat","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chong Kun Dang Pharm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Chong Kun Dang Pharm \/ Not Applicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Nafamostat","moa":"Serine endopeptidase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sankyo \/ Not Applicable"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Nafamostat","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ensysce Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ensysce Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Lowell Therapeutics","sponsor":"AcelRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Nafamostat","moa":"Serine protease","graph1":"Hematology","graph2":"Undisclosed","graph3":"Lowell Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lowell Therapeutics \/ AcelRx Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Lowell Therapeutics \/ AcelRx Pharmaceuticals"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Nafamstat Mesylate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ensysce Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ensysce Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Nafamostat","moa":"Serine protease","graph1":"Hematology","graph2":"Phase II","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"AcelRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AcelRx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Quotient Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Nafamostat Mesylate","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ensysce Biosciences \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Ensysce Biosciences \/ Quotient Sciences"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Nafamostat Mesylate","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ensysce Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ensysce Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Ensysce Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Nafamostat Mesylate","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Quotient Sciences \/ Ensysce Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Ensysce Biosciences"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Nafamostat","moa":"","graph1":"Hematology","graph2":"Phase III","graph3":"AcelRx Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"AcelRx Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"AcelRx Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Nafamostat","moa":"","graph1":"Hematology","graph2":"Phase III","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AcelRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AcelRx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Talphera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Nafamostat","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Talphera","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Talphera \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Talphera \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Nafamostat

    Menu

    Nafamostat

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Quotient Sciences

                            United Kingdom
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothQuotient Sciences- Molecule to Cure. Fast.

                            Lead Product(s) : Oxycodone Prodrug,Nafamostat

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Ensysce Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ensysce Biosciences' PF614-MPAR Enters Final Stage of Phase 1 Study

                            Details : PF614-MPAR (oxycodone prodrug) binds and inhibits adenylyl-cyclase and hyperpolarisation of neurons, and decreased excitability, thus reduces severe pain. It is the first opioid drug product that has both abuse deterrent properties as well as overdose pr...

                            Brand Name : PF614-MPAR

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 25, 2023

                            Lead Product(s) : Oxycodone Prodrug,Nafamostat

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Ensysce Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Quotient

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Talphera

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Talphera

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nafamostat

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Talphera Enrolls First Patient in Trial for Nafamostat in Extracorporeal Circuit

                            Details : Talphera's lead product candidate, Niyad is a lyophilized formulation of nafamostat mesylate and is currently being studied under an IDE as an anticoagulant for the extracorporeal circuit.

                            Brand Name : Niyad

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 19, 2024

                            Lead Product(s) : Nafamostat

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AcelRx Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            AcelRx Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nafamostat

                            Therapeutic Area : Hematology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study

                            Details : Niyad (a lyophilized formulation of nafamostat), an investigational broad-spectrum serine protease inhibitor with anticoagulant, anti-inflammatory, mucus clearing and potential anti-viral activities, towards an FDA approval.

                            Brand Name : Niyad

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 03, 2023

                            Lead Product(s) : Nafamostat

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AcelRx Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            AcelRx Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nafamostat

                            Therapeutic Area : Hematology

                            Study Phase : Phase III

                            Sponsor : H.C. Wainwright & Co.

                            Deal Size : $26.3 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            AcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market Under ...

                            Details : The net proceeds will be used to advance Niyad (nafamostat), an investigational broad-spectrum serine protease inhibitor with anticoagulant, anti-inflammatory, mucus clearing and potential anti-viral activities, towards an FDA approval.

                            Brand Name : Niyad

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 21, 2023

                            Lead Product(s) : Nafamostat

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase III

                            Sponsor : H.C. Wainwright & Co.

                            Deal Size : $26.3 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Ensysce Biosciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Ensysce Biosciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxycodone Prodrug,Nafamostat

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ensysce Biosciences to Present its Overdose Protection Program at the 4th Annual NIH 'Helping End Addiction Lo...

                            Details : PF614-MPAR (oxycodone prodrug) binds and inhibits adenylyl-cyclase and hyperpolarisation of neurons, and decreased excitability, thus reduces severe pain. It is the first opioid drug product that has both abuse deterrent properties as well as overdose pr...

                            Brand Name : PF614-MPAR

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 14, 2023

                            Lead Product(s) : Oxycodone Prodrug,Nafamostat

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ensysce Biosciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Ensysce Biosciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxycodone Prodrug,Nafamostat

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Quotient Sciences

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Ensysce Biosciences and Quotient Sciences Announce a Partnership on the Development and Clinical Testing of En...

                            Details : PF614-MPAR (oxycodone prodrug) is a novel opioid combination product for the potential treatment of chronic pain that is designed to prevent both abuse and overdose. This partnership serves as validation of the mission and ultimately the platforms.

                            Brand Name : PF614-MPAR

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 31, 2022

                            Lead Product(s) : Oxycodone Prodrug,Nafamostat

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Quotient Sciences

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            AcelRx Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            AcelRx Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nafamostat

                            Therapeutic Area : Hematology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AcelRx Pharmaceuticals Announces Publication of Clinical Data Finding Potential Benefits of Nafamostat Compare...

                            Details : Study results demonstrate that nafamostat had similar efficacy as citrate, while providing lower toxicity and lower costs to the hospital over standard citrate anticoagulation.

                            Brand Name : Niyad

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 29, 2022

                            Lead Product(s) : Nafamostat

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Ensysce Biosciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Ensysce Biosciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxycodone Prodrug,Nafamostat,Naltrexone Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ensysce Biosciences Achieves Successful Completion of Part A of MultipleAscending Dose (MAD)/Bioequivalents (B...

                            Details : The Part A of the trial evaluated three dose levels of PF614 showed positive review from the Phase 1b tria, independent Safety Review Committee allowed the trial to proceed to the next dose level.

                            Brand Name : PRF06104

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 04, 2022

                            Lead Product(s) : Oxycodone Prodrug,Nafamostat,Naltrexone Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Lowell Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Lowell Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nafamostat

                            Therapeutic Area : Hematology

                            Study Phase : Undisclosed

                            Sponsor : AcelRx Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            AcelRx Pharmaceuticals to Acquire Lowell Therapeutics and Reports Third Quarter 2021 Financial Results

                            Details : The agreement to acquire Lowell will also include LTX-608, Lowell's proprietary nafamostat formulation for direct IV infusion being developed for the treatment of acute respiratory distress syndrome (ARDS) and disseminated intravascular coagulation (DIC)...

                            Brand Name : LTX-608

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 15, 2021

                            Lead Product(s) : Nafamostat

                            Therapeutic Area : Hematology

                            Highest Development Status : Undisclosed

                            Sponsor : AcelRx Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Ensysce Biosciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Ensysce Biosciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nafamostat

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ensysce Biosciences’ Covistat Subsidiary “At Home Coronavirus Pill” Commencing to Phase 2 Clinical Devel...

                            Details : Covistat will present a summary of its findings that it believes demonstrate the ability of nafamostat, delivered to airways, to inhibit SARS-CoV-2 viral infection and increase mucocilliary clearance in the human airway.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 07, 2021

                            Lead Product(s) : Nafamostat

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth